K
26.89
0.94 (3.62%)
| Penutupan Terdahulu | 25.95 |
| Buka | 25.93 |
| Jumlah Dagangan | 590,362 |
| Purata Dagangan (3B) | 649,209 |
| Modal Pasaran | 1,962,190,208 |
| Harga / Jualan (P/S) | 4.07 |
| Harga / Buku (P/B) | 4.29 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Oct 2024 |
| Margin Keuntungan | -3.52% |
| Margin Operasi (TTM) | 9.63% |
| EPS Cair (TTM) | -0.240 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 72.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2.17% |
| Nisbah Semasa (MRQ) | 3.66 |
| Aliran Tunai Operasi (OCF TTM) | 44.03 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 25.15 M |
| Pulangan Atas Aset (ROA TTM) | -1.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -3.81% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Menurun | Bercampur |
| Drug Manufacturers - Specialty & Generic (Global) | Menurun | Bercampur | |
| Stok | Kiniksa Pharmaceuticals, Ltd. | Menurun | Menaik |
AISkor Stockmoo
-0.4
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | -5.0 |
| Volatiliti Harga | -1.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.40 |
|
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.82% |
| % Dimiliki oleh Institusi | 96.03% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 45.00 (Jefferies, 67.35%) | Beli |
| Median | 40.00 (48.75%) | |
| Rendah | 34.00 (Wedbush, 26.44%) | Beli |
| Purata | 39.67 (47.53%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 22.86 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Jefferies | 29 Apr 2025 | 45.00 (67.35%) | Beli | 25.88 |
| Wedbush | 16 Apr 2025 | 34.00 (26.44%) | Beli | 20.54 |
| Citigroup | 13 Mar 2025 | 40.00 (48.75%) | Beli | 22.16 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| PATEL SANJ K | - | 26.70 | -2,349 | -62,718 |
| TESSARI EBEN | - | 26.74 | -12,000 | -320,880 |
| Jumlah Keseluruhan Kuantiti Bersih | -14,349 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -383,598 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 26.72 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| PATEL SANJ K | Pegawai | 20 May 2025 | Jual automatik (-) | 2,349 | 26.70 | 62,718 |
| PATEL SANJ K | Pegawai | 20 May 2025 | Pelaksanaan pilihan | 2,349 | - | - |
| TESSARI EBEN | Pegawai | 19 May 2025 | Jual automatik (-) | 12,000 | 26.74 | 320,880 |
| TESSARI EBEN | Pegawai | 19 May 2025 | Pelaksanaan pilihan | 7,000 | - | - |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |